SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of…

Denali Therapeutics Inc. · PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 3, 2026 at 16:01 ET

Denali Therapeutics reported Q3 2026 AVLAYAH net product revenue of $17.8M, its second full commercial quarter, and guided Q4 2026 revenue to $30.0M-$32.0M. Net income of $70.1M included a one-time $194.0M gain on sale of a Priority Review Voucher, while operating loss was $126.8M. Cash and securities totaled $1.0B.

  • AVLAYAH net product revenue $17.8M in Q3 2026 (second full commercial quarter).
  • Q4 2026 net product revenue guidance of $30.0M-$32.0M.
  • Net income $70.1M vs net loss $126.9M in Q3 2025; includes $194.0M one-time gain on sale of Priority Review Voucher.
  • Operating loss $126.8M vs $137.4M in Q3 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access